九洲药业(603456) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,490,269,186.29, a year-on-year increase of 0.98% compared to CNY 1,475,743,576.44 in the same period last year[3]. - The net profit attributable to shareholders was CNY 250,202,958.78, reflecting a growth of 5.68% from CNY 236,758,875.39 in the previous year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 250,663,852.13, up 7.17% from CNY 233,891,236.38 year-on-year[5]. - The basic earnings per share for the period was CNY 0.28, an increase of 7.69% from CNY 0.26 in the previous year[3]. - Total operating revenue for Q1 2025 reached ¥1,490,269,186.29, a slight increase of 1.0% compared to ¥1,475,743,576.44 in Q1 2024[19]. - Net profit for Q1 2025 was ¥249,898,291.04, representing an increase of 5.6% from ¥236,172,887.54 in Q1 2024[20]. - Earnings per share for Q1 2025 was ¥0.28, up from ¥0.26 in Q1 2024[21]. - The total comprehensive income for Q1 2025 was ¥253,262,352.60, an increase from ¥238,535,809.13 in Q1 2024[21]. Cash Flow - The net cash flow from operating activities was CNY 285,673,256.24, a significant increase of 309.34% compared to a negative cash flow of CNY -136,464,671.63 in the same period last year[3][8]. - Cash flow from operating activities generated ¥285,673,256.24, a significant recovery from a negative cash flow of -¥136,464,671.63 in Q1 2024[23]. - The net cash flow from investing activities was -$275,001,468.94, compared to -$233,704,966.26 in the previous period, indicating an increase in cash outflow by approximately 17.6%[25]. - Cash inflow from financing activities totaled $300,000,000.00, a significant decrease from $1,548,800,000.00 in the prior period, reflecting a decline of about 80.6%[25]. - The net cash flow from financing activities was $459,978.90, a sharp decline from $952,505,601.67, indicating a decrease of around 99.9%[25]. - The net increase in cash and cash equivalents was $15,269,631.18, a significant drop from $583,036,446.15, reflecting a decrease of about 97.4%[25]. - The ending balance of cash and cash equivalents was $2,608,951,626.14, down from $3,659,105,798.05, indicating a decline of approximately 28.7%[25]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 11,030,929,211.43, a decrease of 0.87% from CNY 11,127,254,062.84 at the end of the previous year[3]. - As of March 31, 2025, the total current assets amounted to RMB 5,968,483,213.11, a decrease from RMB 6,071,494,807.15 as of December 31, 2024, reflecting a decline of approximately 1.7%[13]. - The total assets as of March 31, 2025, were RMB 11,030,929,211.43, down from RMB 11,127,254,062.84, reflecting a decrease of approximately 0.9%[14]. - Total liabilities decreased to RMB 2,164,356,374.45 from RMB 2,517,671,243.17, a reduction of about 14%[15]. - The total equity remained stable at RMB 895,235,828.00, unchanged from the previous period[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 53,978[10]. - The largest shareholder, Zhejiang Zhongbei Jiuzhou Group Co., Ltd., holds 31.67% of the shares, with 51,500,000 shares pledged[10]. Operational Focus - The company is focused on expanding its CDMO business, benefiting from a steady increase in orders and a rich pipeline of clients and products[5]. Other Financial Metrics - The company's return on equity (ROE) increased to 2.89%, up 0.12 percentage points from 2.77% in the previous year[3]. - Research and development expenses for Q1 2025 totaled ¥67,680,193.57, an increase of 8.3% compared to ¥64,871,910.84 in Q1 2024[20]. - The company reported a decrease in financial expenses, with net financial costs of -¥4,451,028.66 in Q1 2025, compared to -¥18,888,019.97 in Q1 2024[20]. - Other comprehensive income after tax for Q1 2025 was ¥3,364,061.56, compared to ¥2,362,921.59 in Q1 2024, reflecting improved financial performance[21]. Accounting Changes - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[25]. - The company is led by Huari Rong, with Sha Yujie responsible for accounting work, and Wu An as the head of the accounting institution[25].